中文
Products

Procalcitonin / Interleukin-6 / C-reactive Protein (PCT/IL-6/CRP) Detection Kit

Procalcitonin / Interleukin-6 / C-reactive Protein (PCT/IL-6/CRP) Detection Kit (Quantum Dots-Based Immunofluorescence Chromatography)

Intended Use

For the in vitro quantitative detection of Procalcitonin (PCT), Interleukin-6 (IL-6) and C-reactive protein (CRP) in human serum, plasma, whole blood, or capillary blood.

Procalcitonin / Interleukin-6 / C-reactive Protein (PCT/IL-6/CRP) Detection Kit

Clinical Department

Clinical Laboratory, Emergency Department/ICU, Infectious Diseases Department, Respiratory Medicine Department, Paediatrics Department, Neonatology Department, Hematology Department, Rheumatology Department, Cardiology Department, etc.

Product Parameters Clinical application

[Product Name]Procalcitonin / Interleukin-6 / C-reactive Protein (PCT/IL-6/CRP) Detection Kit

[Sample Type]Serum, plasma, whole blood, or capillary blood

[Intended Use]
For the in vitro quantitative detection of Procalcitonin (PCT), Interleukin-6 (IL-6) and C-reactive protein (CRP) in human serum, plasma, whole blood, or capillary blood.

[Clinical Department]
Clinical Laboratory, Emergency Department/ICU, Infectious Diseases Department, Respiratory Medicine Department, Paediatrics Department, Neonatology Department, Hematology Department, Rheumatology Department, Cardiology Department, etc.


Product Parameters

Item

PCT/IL-6/CRP

Test Time

18min

Sample Type

Serum, plasma, whole blood, or capillary blood

Sensitivity

0.01ng/mL; 0.002ng/mL; 0.1mg/L

Storage Condition

4-30℃

Packing Specification

25 Tests/Kit; 50 Tests/Kit


PCT, IL-6 and CRP are commonly used clinical inflammatory biomarkers, primarily employed for assessing infection type, its severity, and the status of the inflammatory response.

PCT increases rapidly within 2–3 hours after bacterial infection, peaks at 12–24 hours after infection, and its level is positively correlated with infection severity. Clinically, this marker is used for auxiliary diagnosis of bacterial infectious diseases, sepsis and septicemia.

IL-6 can increase within 1–2 hours after infection or tissue injury, earlier than CRP and PCT, acting as an "initiator" of the inflammatory response. Its level correlates with the activity of inflammation and is clinically used for monitoring the body's immune status and inflammatory response.

CRP is one of the acute-phase reactant proteins; it begins to increase 6–8 hours after infection or tissue injury and peaks at 24–48 hours, with the magnitude of elevation positively correlated to the severity of infection or inflammation.

1. Combined testing of PCT, IL-6, and CRP enables full-cycle coverage from infection onset to progression, allowing precise differentiation between bacterial infections, viral infections, and non-infectious inflammation. It is particularly suitable for cases with atypical symptoms in the early infection stage or ambiguous results from single-biomarker testing.

2. Combined testing of PCT, IL-6, and CRP facilitates dynamic assessment of disease progression in critically ill patients such as those with severe pneumonia or sepsis, providing reliable evidence for determining treatment efficacy and prognosis.

3. Combined testing of PCT, IL-6, and CRP can guide the rational use of antibiotics, preventing unnecessary antibiotic overuse.


微信公众平台

官网二维码